Jo-1 Antibody Detection Kit

This product is used to determine the concentration of Jo-1 antibodies in serum or plasma samples.

The Jo-1 Antibody Detection Kit (ELISA) utilizes enzyme-linked immunosorbent assay (ELISA) for in vitro diagnosis as an auxiliary differential method for diagnosing polymyositis (PM) and dermatomyositis (DM).

Polymyositis (PM) and dermatomyositis (DM) are common rheumatic diseases that often affect multiple systems such as the skin, heart, gastrointestinal tract, muscles, and lungs. They are systemic autoimmune diseases. Anti-Jo-1 antibodies are the most common myositis-specific autoantibodies and are one type of anti-ENA antibodies. Anti-Jo-1 antibodies have a strong specificity for the diagnosis of polymyositis and dermatomyositis, with a positive rate of about 25% in polymyositis and 7.1% in dermatomyositis. The positive rate is as high as 60% in PM/DM patients with combined interstitial lung lesions.

MDA5 Antibody Detection Kit

This kit is used to determine the concentration of melanoma differentiation gene 5 antibody in serum or plasma samples.

The Melanoma Differentiation Gene 5 Antibody Detection Kit (ELISA) uses enzyme-linked immunosorbent assay (ELISA) for in vitro diagnosis as an auxiliary means of differential diagnosis of dermatomyositis-related diseases.

Dermatomyositis (DM) is a common life-threatening inflammatory myopathy in clinical practice, mainly affecting the skin and muscles, and is an autoimmune disease. In clinical practice, we have observed that patients with DM involving the skin or with the skin as the main affected organ, which we call "amyopathic dermatomyositis (CADM)", have a very poor prognosis. According to existing reports and clinical data, the reason why DM/CADM has a worse prognosis than PM is that the incidence of interstitial pneumonia (ILD) is extremely high, which is the primary cause of death in DM/CADM patients.

Anti-MDA5 antibody is not only a specific antibody for DM/CADM combined with ILD, but also a serological marker for rapidly progressive interstitial lung disease in patients with DM/CADM. The antibody level is highly positively correlated with the occurrence and severity of interstitial lung disease, and is also highly positively correlated with the occurrence of skin ulcers and vasculitis.

TIF1-γ Antibody Detection Kit

This product is used to determine the concentration of transcription intermediary factor TIF1-γ antibodies in serum or plasma samples.

The Transcription Intermediate Factor 1-γ Antibody Detection Kit (ELISA) uses enzyme-linked immunosorbent assay (ELISA) for in vitro diagnosis as an auxiliary identification method for diagnosing dermatomyositis-related diseases.

Idiopathic inflammatory myopathy (IIM) is an autoimmune disease characterized by chronic inflammation of skeletal muscle, which can cause damage to multiple organs such as skin and lungs. It currently mainly includes dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), amyopathic dermatomyositis (ADM) and immune-mediated necrotizing myopathy (IMNM).

Anti-TIF1-γ antibody is one of myositis-specific autoantibodies, which is significantly associated with adult tumor-related myositis. It can also be seen in children with juvenile dermatomyositis but is not associated with tumors. TIF1-γ negatively regulates the TGF-β signaling pathway, leading to Th17/Treg immune imbalance. Secondly, inactivation of Samd4 ubiquitination causes a decrease in the repair ability of damaged blood vessels and muscle tissue, which jointly contributes to the pathogenesis of DM.